Literature DB >> 11568086

Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

M Sjögren1, H Vanderstichele, H Agren, O Zachrisson, M Edsbagge, C Wikkelsø, I Skoog, A Wallin, L O Wahlund, J Marcusson, K Nägga, N Andreasen, P Davidsson, E Vanmechelen, K Blennow.   

Abstract

BACKGROUND: Tau protein and the 42-amino acid form of beta-amyloid (Abeta42) measured in cerebrospinal fluid (CSF) have been proposed as potential biochemical diagnostic markers for Alzheimer disease. For the introduction of these assays in clinical practice, adequate reference values are of importance.
METHODS: CSF samples were obtained from 231 neurologically and psychiatrically healthy individuals, 21-93 years of age, all with a MiniMental State examination score of 28 or above. Standardized ELISAs were used to measure tau and Abeta42 in CSF. Following IFCC recommendations, we used a rank-based method; the 0.90 and 0.10 fractiles were estimated to establish reference values for CSF-tau and CSF-Abeta42, respectively. Putative confounding factors, such as the influence of the passage of proteins from peripheral blood to CSF, influence of dysfunction of the blood-brain barrier, and freezing and thawing of CSF, were investigated.
RESULTS: A correlation with age was found for CSF-tau (r = 0.60; P <0.001). Therefore, separate reference values for different age groups were established for CSF-tau: <300 ng/L in the group 21-50 years of age, <450 ng/L in the group 51-70 years of age, and <500 ng/L in the group 71-93 years of age. CSF-Abeta42 did not correlate with age (r = -0.045), and the reference value was set to >500 ng/L. No correlation was found between blood-brain barrier function and CSF-tau or CSF-Abeta42.
CONCLUSIONS: These reference values can be applied when using CSF-tau and CSF-Abeta42 in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568086

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  115 in total

1.  The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.

Authors:  Whitney Wharton; James H Stein; Claudia Korcarz; Jane Sachs; Sandra R Olson; Henrik Zetterberg; Maritza Dowling; Shuyun Ye; Carey E Gleason; Gail Underbakke; Laura E Jacobson; Sterling C Johnson; Mark A Sager; Sanjay Asthana; Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

3.  No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Authors:  Jan J Krut; Richard W Price; Henrik Zetterberg; Dietmar Fuchs; Lars Hagberg; Aylin Yilmaz; Paola Cinque; Staffan Nilsson; Magnus Gisslén
Journal:  Virulence       Date:  2016-07-19       Impact factor: 5.882

4.  Tau missing from CSF: a case report.

Authors:  Antonella Alberici; Mario Armani; Anna Paterlini; Luisa Benussi; Francesca Nicosia; Roberta Ghidoni; Simona Signorini; Maria Cotelli; Giovanni B Frisoni; Cristina Geroldi; Carlo P Trevisan; John H Growdon; Barbara Borroni; Alessandro Padovani; Paolo M Rossini; Giuliano Binetti
Journal:  J Neurol       Date:  2007-02-03       Impact factor: 4.849

5.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

6.  Mild Alzheimer's disease: a "position paper".

Authors:  J Delrieu; T Voisin; S Andrieu; S Belliard; J Belmin; F Blanchard; M Ceccaldi; J F Dartigues; B Defontaines; S Lehericy; C Mekies; O Moreaud; L Naccache; F Nourhashemi; P J Ousset; F Pasquier; P Payoux; F Puisieux; P Robert; J Touchon; B Vellas; B Dubois
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

7.  Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Moeko Noguchi-Shinohara; Tsuyoshi Hamaguchi; Ichiro Nozaki; Kenji Sakai; Masahito Yamada
Journal:  J Neurol       Date:  2011-03-01       Impact factor: 4.849

8.  Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications.

Authors:  Khader M Hasan; John A Lincoln; Flavia M Nelson; Jerry S Wolinsky; Ponnada A Narayana
Journal:  Magn Reson Imaging       Date:  2014-12-05       Impact factor: 2.546

9.  Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

Authors:  Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale
Journal:  Cereb Cortex       Date:  2010-01-04       Impact factor: 5.357

10.  Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates.

Authors:  Stefan Winblad; Christer Jensen; Jan-Eric Månsson; Lena Samuelsson; Christopher Lindberg
Journal:  Behav Brain Funct       Date:  2010-05-19       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.